Human Metabolome Technologies (TSE:6090) Stock Based Compensation: 円0.0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:6090 Human Metabolome Technologies Inc TSE:6090
60 GF Score
Price 円596.00
GF Value 円531.03
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Human Metabolome Technologies Stock Based Compensation?

Human Metabolome Technologies TSE:6090 +0.34% 60 Stock Based Compensation is 円0.0 Mil as of Dec. 2025. GuruFocus rates TSE:6090 with a GF Score™ of 60/100 and a GF Value™ of 円531.03 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Human Metabolome Technologies's Stock Based Compensation for the three months ended in Dec. 2025 was 円0.0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was 円0.0 Mil.

Human Metabolome Technologies Stock Based Compensation Related Terms

Human Metabolome Technologies Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Human Metabolome Technologies's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Human Metabolome Technologies Stock Based Compensation Chart

Human Metabolome Technologies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Jun20 Jun21 Jun22 Jun23 Jun24
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.12 3.17 1.14 0.47 0.00

Human Metabolome Technologies Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:6090
60GF Score
Human Metabolome Technologies Inc TSE:6090
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Human Metabolome Technologies Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.0 Mil.

What does a Stock Based Compensation of 円0.0 Mil mean?
Human Metabolome Technologies (TSE:6090) has a Stock Based Compensation of 円0.0 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Human Metabolome Technologies and its competitors.
Is Human Metabolome Technologies' Stock Based Compensation too high?
Human Metabolome Technologies' current Stock Based Compensation is 円0.0 Mil. Overall, Human Metabolome Technologies has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Human Metabolome Technologies' Stock Based Compensation compare to TMO and DHR?
Human Metabolome Technologies' Stock Based Compensation of 円0.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Diagnostics & Research company?
A good Stock Based Compensation depends on the Medical Diagnostics & Research industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Human Metabolome Technologies and its competitors. Human Metabolome Technologies's current Stock Based Compensation is 円0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Human Metabolome Technologies stock overvalued right now?
Based on GuruFocus' analysis, Human Metabolome Technologies (TSE:6090) is currently considered Modestly Overvalued. The stock's GF Value™ is 円531.03, compared to a current price of 円596.00 — trading 12.2% above its estimated fair value. The current Stock Based Compensation is 円0.0 Mil. Human Metabolome Technologies' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Human Metabolome Technologies (TSE:6090), the current Stock Based Compensation is 円0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?

Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be overvalued. The current stock price of 円596.00 is trading 12.2% above its estimated GF Value™ of 円531.03. GuruFocus considers Human Metabolome Technologies to be Modestly Overvalued.

Key valuation signals for TSE:6090:

  • Stock Based Compensation: 円0.0 Mil
  • GF Value™: 円531.03 vs. price of 円596.00 (12.2% above fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Human Metabolome Technologies Business Description

Address Yamagata Prefecture Kakuganji Water 246-2, Tsuruoka, JPN, 997-0052
Human Metabolome Technologies Inc is involved in the search and diagnosis of biomarkers and commercialization in the field of drug development.
60GF Score

Get the complete analysis for TSE:6090

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円596.00
Price
円531.03
GF Value